Researchers at Johns Hopkins Medicine have unveiled a crucial gene, identified as KLF5, that appears to be a significant orchestrator of pancreatic cancer’s formidable ability to spread. This finding moves beyond the traditional focus on DNA mutations, highlighting the pivotal role of epigenetics—changes that alter gene expression without modifying the underlying genetic code itself. In meticulously controlled laboratory environments using cultured cells, KLF5 demonstrated a potent capacity to fuel tumor proliferation and facilitate invasion, not by corrupting the DNA sequence, but by fundamentally reconfiguring the organizational architecture and chemical modifications of the genome. These epigenetic alterations act as master switches, dictating whether specific genes are activated or silenced, thereby controlling cellular behavior.
The concept that epigenetic alterations represent a primary mechanism in the genesis and aggressive progression of cancer metastasis is gaining substantial traction, according to Dr. Andrew Feinberg, a distinguished Bloomberg Professor at Johns Hopkins University, whose expertise spans the schools of medicine, engineering, and public health. Dr. Feinberg’s prior investigative work, published in 2017, provided compelling evidence that the most prevalent form of pancreatic cancer is characterized by extensive epigenetic modifications within primary tumors. This earlier research suggested that these epigenetic shifts, rather than novel DNA mutations, were the driving force behind the cancer’s propensity to disseminate throughout the body. The latest discoveries, detailed in the journal Molecular Cancer and partially subsidized by grants from the National Institutes of Health, serve as a significant expansion upon this foundational knowledge, illuminating novel avenues for therapeutic intervention.
To pinpoint the genes exerting the most profound influence on cancer cell proliferation, the investigative team employed CRISPR, a revolutionary gene-editing technology. This sophisticated tool allows for the precise and selective deactivation of specific genes. By systematically silencing genes one by one, the scientists meticulously observed which gene knockouts had the most substantial effect in impeding or halting the growth of cancer cells. Among the comprehensive array of genes subjected to this rigorous testing, KLF5 emerged as a standout candidate. Its inactivation yielded the most significant impact in suppressing the growth and migratory capabilities of metastatic cancer cells. Furthermore, an analysis of patient-derived samples revealed that a notable majority, 10 out of 13 individuals diagnosed with pancreatic cancer, exhibited elevated levels of KLF5 activity in at least one metastatic tumor when compared to their original primary tumor.
Delving deeper into the functional role of KLF5, subsequent experiments conclusively demonstrated its direct influence on the intricate process of DNA packaging within cells. This packaging, a highly regulated phenomenon, is instrumental in determining the accessibility of genes, thereby dictating which genes are actively transcribed and which remain dormant. The research team discovered that even marginal increases in KLF5 activity could dramatically enhance a cancer cell’s capacity for proliferation and dissemination. Dr. Feinberg suggests that this finding carries significant therapeutic implications, positing that treatments aimed at combating pancreatic cancer metastasis may not necessitate the complete eradication of KLF5’s function to achieve a beneficial outcome. He further notes the promising development of several experimental therapeutic agents specifically designed to target KLF5.
Beyond its direct impact on cancer cell behavior, the study also illuminated KLF5’s role as a regulatory hub for other genes, including NCAPD2 and MTHFD1. Crucially, this regulation was observed exclusively in metastatic pancreatic cancer cells, distinguishing them from primary tumor cells cultured in vitro. These identified genes are classified as epigenetic modifiers, underscoring their function in modulating gene expression through the addition of chemical groups to DNA and alterations to its structural configuration. Kenna Sherman, the lead author of the study and a doctoral candidate in the Johns Hopkins Human Genetics and Genomics program, articulated that these findings contribute to a growing body of evidence suggesting that the development of cancer metastases is not primarily driven by additional mutations in the initial tumor. Instead, she posits that it is rather a consequence of accumulating epigenetic modifications that empower the cancer to thrive and expand. Sherman further elaborated that KLF5 appears to function as a master regulator, initiating these epigenetic shifts and influencing a network of genes known to govern cellular invasion and the development of resistance to therapeutic interventions.
The research underpinning these groundbreaking discoveries received substantial support from various entities, including grants from the National Institutes of Health (under award numbers CA54358, R01HG010889, R01HG013409, and T32GM148383), a Celgene License Pathway Agreement, and a generous contribution from the friends and family of Jasmine Lampadarios. The collaborative effort involved a multidisciplinary team of researchers. From Johns Hopkins University, contributions were made by Masahiro Maeda, Weiqiang Zhou, Jiaqi Cheng, Yuta Nihongaki, Adrian Idrizi, Rakel Tryggvadottir, Oscar Camacho, Michael Koldobskiy, Barbara Slusher, and Hongkai Ji. Additional expertise was provided by Xingbo Shang and Andre Levchenko from Yale University, and Jimin Min and Anirban Maitra from NYU Langone Health. This collective endeavor underscores the complex and multifaceted nature of cancer research, requiring the convergence of diverse scientific disciplines and institutional collaborations to unravel the intricate mechanisms of disease. The identification of KLF5 as a central epigenetic regulator in pancreatic cancer metastasis offers a critical new perspective and a promising target for future therapeutic strategies aimed at improving patient outcomes.
About the Author
